A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Basic Clin Androl
Huvudupphovsmän: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2018
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://ncbi.nlm.nih.gov/pubmed/30026950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12610-018-0074-2
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk